12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pregabalin controlled-release: Phase III data

Top-line data from an international Phase III trial in patients with epilepsy showed that once-daily 165 and 330 mg pregabalin CR as adjunctive treatment each missed the primary endpoint of reducing the log-transformed 28-day seizure rate for all partial onset seizures collected during the 14-week double-blind treatment period from baseline vs. placebo (p=0.907 for high-dose; low-dose p-value not disclosed). Pfizer did not disclose detailed data for the primary endpoint, but said the non-significant...

Read the full 344 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >